What Does H. Pylori Cause? Ulcers, Cancer & More

Helicobacter pylori, a spiral-shaped bacterium that colonizes the stomach lining, is directly responsible for the vast majority of peptic ulcers and is the single strongest known risk factor for gastric cancer. But the list of conditions linked to this infection extends well beyond the stomach. Research has tied H. pylori to a specific type of stomach lymphoma, iron deficiency anemia, a bleeding disorder called immune thrombocytopenic purpura, and possibly even fatty liver disease. At the same time, the bacterium appears to have a paradoxical protective side, with infections correlating to lower rates of certain esophageal cancers and allergic diseases. Roughly half the world’s population carries H. pylori, yet only a fraction develops serious illness from it, which makes untangling what the bacterium actually does in any given person more complicated than a simple list of diseases.

Peptic Ulcers and Chronic Gastritis

The link between H. pylori and ulcers was the discovery that upended decades of medical thinking. Before the 1980s, doctors blamed ulcers on stress and spicy food. Now we know H. pylori infection is the dominant cause of both gastric ulcers (in the stomach) and duodenal ulcers (in the first section of the small intestine). The bacterium burrows into the mucus layer that protects the stomach lining and triggers chronic inflammation, or gastritis, which in many people never progresses beyond mild irritation but in others leads to open sores.

When H. pylori settles predominantly in the antrum, the lower portion of the stomach, it ramps up the release of the hormone gastrin, which in turn drives the stomach to produce more acid than normal. That excess acid washes into the duodenum, damages the lining there, and creates the conditions for duodenal ulcers to form. The bacterium’s own toxins, particularly CagA and VacA, amplify mucosal inflammation and weaken the stomach’s defenses further.¹ This is why eradication therapy, killing the infection with antibiotics, cures most ulcers and dramatically reduces their recurrence.

How It Survives Stomach Acid

The stomach is one of the harshest environments in the body, with a pH that can drop below 2. Most bacteria cannot survive there for more than a few minutes. H. pylori thrives because it has evolved sophisticated acid-neutralizing machinery, including the enzyme urease, which breaks down urea into ammonia and carbon dioxide, creating a local alkaline shield around the bacterium. This buffering system lets H. pylori swim through the acidic gastric juice and settle into the more neutral mucus layer coating the stomach wall.² Once there, it can persist for decades, often for a person’s entire life if untreated.

H. pylori also reshapes the stomach’s microbial community. In infected individuals, the bacterium becomes the dominant species and significantly reduces the diversity of other stomach microbes.³ What that microbial takeover means for disease risk is still being worked out, but it underscores that H. pylori does not just occupy the stomach quietly. It transforms the environment around it.

Gastric Cancer

The World Health Organization classified H. pylori as a Group 1 carcinogen back in 1994, and the evidence has only grown stronger since. A large Korean study of nearly 7 million people found that H. pylori infection increased gastric cancer risk roughly sixfold.⁴ That same study confirmed the sequential progression known as the Correa pathway: chronic infection leads to chronic gastritis, then to atrophic gastritis (where acid-producing cells are lost), then to intestinal metaplasia (where the stomach lining starts to resemble the intestinal lining), then to adenoma, and finally to cancer.

Not every step carries equal weight. The Korean data showed that about 36% of H. pylori’s effect on gastric cancer was channeled through the adenoma stage, while only about 3% was mediated through atrophic gastritis and intestinal metaplasia alone.⁴ The practical takeaway is that H. pylori prevention and early eradication represent the single most important lever for reducing gastric cancer incidence.

Still, only a minority of infected people ever develop cancer. Classical bacterial virulence markers like CagA-positive strains explain part of this variation, but not all of it. Researchers have increasingly turned to genome-wide analysis of bacterial strains, looking for patterns across the entire H. pylori genome that predict which infections are most dangerous.⁵ Your own genetics also matter: certain variations in the gene for interleukin-1β, an inflammatory signaling molecule, appear to increase gastric cancer susceptibility specifically in people who carry H. pylori.⁶ Though not every study has replicated this gene-infection link across all populations.⁷

Gastric MALT Lymphoma

Beyond the common adenocarcinoma, H. pylori is the primary driver of a rarer stomach cancer: mucosa-associated lymphoid tissue (MALT) lymphoma. This low-grade B-cell lymphoma accounts for roughly 7 to 9% of all B-cell lymphomas and is one of the clearest examples in medicine of a cancer caused directly by chronic infection.⁸ The tumor depends on the ongoing immune stimulation that H. pylori provides, essentially feeding on the inflammatory response the infection generates.

This dependence is what makes the treatment so unusual. In early-stage gastric MALT lymphoma, simply eradicating H. pylori with antibiotics leads to complete remission in roughly 60 to 90% of patients, without chemotherapy or radiation.⁸ A long-term study of 105 patients found that antibiotic eradication achieved histological regression in about 76% of cases, with many remissions holding at a median follow-up of over six years.⁹ Not all cases respond, though. Tumors carrying certain genetic changes, such as the t(11;18) translocation, can grow independently of H. pylori stimulation and require conventional cancer treatment.⁸ There is even evidence that some higher-grade MALT lymphomas, if caught at an early stage with limited spread, may still regress after eradication therapy.¹⁰

Iron Deficiency Anemia

H. pylori’s effects extend beyond the stomach lining itself. Multiple meta-analyses have found that persistent infection can lead to iron deficiency and iron deficiency anemia, with the association being particularly strong in children and adolescents.¹¹ The mechanisms likely involve a combination of factors: the chronic inflammation reduces iron absorption, the bacterium itself competes for available iron, and in some cases the low-grade bleeding from gastritis contributes to iron loss. When standard iron supplementation fails to resolve anemia in a child, testing for H. pylori is worth considering because eradicating the infection often allows iron levels to recover.

Immune Thrombocytopenic Purpura

One of the more surprising H. pylori connections is with immune thrombocytopenic purpura (ITP), a condition in which the immune system attacks and destroys platelets, leading to easy bruising and bleeding. Researchers have found that eradicating H. pylori in infected ITP patients leads to a meaningful rise in platelet counts. In one study, platelet counts increased nearly threefold within a year of successful eradication, compared with only modest changes in patients whose infection persisted.¹² In many responders, the anti-platelet autoimmune response resolves completely and stays gone for years, suggesting the infection was actually driving the autoimmune attack.¹³

Response rates vary. One study of 201 ITP patients found about 59% responded to H. pylori eradication therapy, with roughly a third of the total achieving a complete platelet response.¹⁴ The connection is strong enough that guidelines in many countries recommend testing ITP patients for H. pylori, though updated pediatric guidelines have moved away from routine testing in children with chronic ITP.¹⁵

Possible Links to Fatty Liver Disease

An emerging area of research connects H. pylori to metabolic dysfunction-associated steatotic liver disease (MASLD), the condition formerly known as non-alcoholic fatty liver disease. A meta-analysis of observational studies found that H. pylori infection is associated with an increased risk of having or developing MASLD.¹⁶ Mouse studies have shown that chronic H. pylori infection worsens liver fat accumulation and insulin resistance when combined with a high-fat diet.¹⁷ The proposed pathway runs through systemic inflammation and impaired insulin signaling.¹⁸

This is still early-stage evidence, however. Observational studies can show correlation but not causation, and fatty liver disease has many risk factors that are hard to separate from H. pylori status. The research is interesting enough to follow but not yet strong enough to change clinical practice.

The Protective Paradox

Here is where H. pylori gets genuinely strange. Despite its clear role in causing stomach disease, the bacterium appears to protect against certain conditions in other parts of the body.

The most studied protective association is with esophageal adenocarcinoma, a cancer of the lower esophagus that has been rising sharply in Western countries as H. pylori prevalence has fallen. H. pylori infection, particularly the strains that cause atrophic gastritis, reduces stomach acid output. Lower acid production means less acid reflux, which means less damage to the esophagus. The infection may also alter levels of ghrelin, a hormone involved in appetite, and trigger programmed cell death in esophageal cancer cells through other pathways.¹⁹ The irony is real: the same acid-reducing effect that makes H. pylori dangerous to the stomach (by enabling the Correa pathway toward gastric cancer) appears to shield the esophagus.

H. pylori has also been inversely associated with asthma and allergic diseases. Epidemiological studies consistently find that infected people are less likely to have asthma, and eradicating H. pylori appears to increase the risk of developing allergic conditions.²⁰ Mouse studies have backed this up, showing that the infection promotes a type of immune tolerance that dampens the overactive immune responses behind allergic disease.²¹ The hypothesized mechanism involves the bacterium encouraging the expansion of regulatory T cells that suppress allergic inflammation.²²

None of this means you should want an H. pylori infection to prevent asthma. The risks from ulcers and gastric cancer are concrete and well-quantified. The protective effects are population-level statistical associations that researchers are still working to fully explain. But the pattern does suggest that H. pylori is not simply a pathogen; it is a co-traveler whose effects on the human body are a mix of harmful and beneficial.

Why Ancestry and Geography Matter

One of the most remarkable findings about H. pylori is that its evolutionary history is intertwined with ours. The bacterium has co-migrated with human populations for at least 60,000 years, and its genetic family tree mirrors human migration patterns. This co-evolution has practical consequences for disease risk.

In a study of two regions in Colombia with similar H. pylori prevalence (around 90%) but dramatically different rates of gastric cancer, the difference was entirely explained by the match between human and bacterial ancestry. On the Pacific coast, where the population has predominantly African ancestry, African-lineage H. pylori strains were relatively harmless. In the highland region of Nariño, where the population is largely Amerindian, those same African-lineage strains were associated with much worse gastric disease.²³ The difference was stark: gastric cancer incidence on the Pacific coast was around 6 per 100,000 people per year, while in Nariño it was 150 per 100,000.²⁴

The implication is that colonization, migration, and the mixing of populations have created mismatches between human and H. pylori genomes that continue to shape who gets cancer today. It also means that global gastric cancer patterns cannot be understood by looking at bacterial virulence or human genetics alone; you have to look at how well the two have been adapted to each other over millennia.

How H. Pylori Spreads

H. pylori is almost always acquired during childhood, and in most cases the infection comes from close family contacts. The bacterium passes from person to person, most likely through oral-oral contact (via saliva or vomit) or the fecal-oral route. Rates of infection are much higher in developing countries and in settings with crowded living conditions and limited sanitation.²⁵ In high-income countries, prevalence has been declining for decades as hygiene and living standards have improved, though it remains common worldwide.

How It Is Diagnosed

Doctors have several ways to detect H. pylori, divided into invasive methods (requiring an endoscopy with biopsy) and non-invasive ones. For most patients who do not need an endoscopy for other reasons, the urea breath test is generally recommended as the first choice. You swallow a capsule or drink containing labeled urea; if H. pylori is present, its urease enzyme breaks down the urea and the labeled carbon appears in your breath. The test is quick, accurate, and also useful for confirming that eradication therapy worked.²⁶

The stool antigen test is another strong non-invasive option, with studies showing sensitivity above 95% in some settings.²⁷ Blood antibody tests (serology), by contrast, perform poorly at distinguishing active infection from past exposure and are generally not recommended for initial diagnosis.²⁷ When an endoscopy is performed, the rapid urease test on biopsy tissue gives results within hours. For children, updated guidelines recommend invasive testing with biopsy and antimicrobial susceptibility analysis, particularly because knowing which antibiotics the specific strain resists is critical for choosing effective treatment.¹⁵

Treatment and the Resistance Problem

Standard H. pylori treatment uses a combination of antibiotics alongside a drug that suppresses stomach acid, typically a proton pump inhibitor. The classic regimen is a triple therapy: a proton pump inhibitor plus two antibiotics, usually amoxicillin and clarithromycin. But rising antibiotic resistance, particularly to clarithromycin, has been eroding the effectiveness of this approach worldwide.

Extending treatment from 7 or 10 days to 14 days improves eradication rates. Quadruple therapies that add bismuth tend to outperform triple therapy, especially when clarithromycin resistance is a concern.²⁸ A prospective trial of bismuth-based quadruple therapy for clarithromycin-resistant infections found eradication rates of about 87% with a 14-day course and about 79% with a 7-day course, though the difference did not reach statistical significance in that particular study.²⁹

Newer acid suppressants like vonoprazan, which blocks acid secretion more consistently than traditional proton pump inhibitors, are showing promise in improving eradication rates when combined with antibiotics.²⁸ The broader trend in H. pylori treatment is moving toward susceptibility-guided therapy, where you test which antibiotics the strain is resistant to before choosing a regimen, rather than relying on a one-size-fits-all approach. Pediatric guidelines already emphasize this, recommending that if susceptibility data is not available, clarithromycin-containing regimens should simply be avoided due to high resistance rates.¹⁵

How Diet Interacts with H. Pylori

H. pylori does not act alone. Dietary factors, particularly salt intake, can amplify the damage. High-salt diets disrupt the stomach’s mucosal barrier, alter H. pylori gene expression in ways that increase virulence, promote oxidative stress, and heighten inflammatory responses. Studies have found that gastric cancer patients tend to have higher sodium intake than healthy controls, and the combination of H. pylori infection and high salt intake appears to compound cancer risk beyond what either factor would produce on its own.³⁰ This is one of the more actionable pieces of the H. pylori puzzle: if you carry the infection, reducing salt intake is a concrete step toward reducing risk while you pursue eradication.

1
PubMed Central. Mechanisms involved in Helicobacter pylori induced duodenal ulcer disease: an overview
2
PubMed Central. Survival of Helicobacter pylori in gastric acidic territory
3
PubMed Central. Helicobacter pylori infection affects the human gastric microbiome, as revealed by metagenomic sequencing
4
PubMed Central. Quantifying the effects of the Correa pathway from Helicobacter pylori infection to gastric cancer: causal inference found in 6.8 million Koreans
5
PubMed Central. Risk prediction of Helicobacter pylori strains across Correa’s cascade via intelligent analysis of genome-wide SNPs
6
PubMed Central. Interleukin‐1B 31 C>T polymorphism combined with Helicobacter pylori ‐modified gastric cancer susceptibility: evidence from 37 studies
7
PubMed. Interleukin 1-beta gene polymorphisms and risk of gastric cancer in Sweden
8
Exploration of Digestive Diseases. Helicobacter pylori and gastric MALT lymphoma: mechanisms of pathogenesis and therapeutic implications
9
PubMed. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type
10
PubMed Central. Regression of gastric high grade mucosa associated lymphoid tissue (MALT) lymphoma after Helicobacter pylori eradication
11
PubMed Central. Helicobacter pylori-Associated Iron Deficiency Anemia in Childhood and Adolescence-Pathogenesis and Clinical Management Strategy
12
Scientific Reports. Helicobacter pylori eradication affects platelet count recovery in immune thrombocytopenia
13
PubMed Central. Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms
14
PubMed Central. Helicobacter pylori induced Immune Thrombocytopenic Purpura and perspective role of Helicobacter pylori eradication therapy for treating Immune Thrombocytopenic Purpura
15
PubMed. Updated joint ESPGHAN/NASPGHAN guidelines for management of Helicobacter pylori infection in children and adolescents (2023)
16
Liver International. Relationship between Helicobacter pylori infection and risk of metabolic dysfunction‐associated steatotic liver disease: An updated meta‐analysis
17
PubMed Central. Helicobacter pylori infection as a risk factor in the development of metabolic dysfunction-associated steatotic liver disease
18
PubMed Central. Helicobacter pylori infection as a contributing factor to metabolic dysfunction-associated steatohepatitis: A population-based insight
19
PubMed Central. Is Helicobacter pylori infection protective against esophageal cancer?
20
PubMed Central. The Protective Effects of Helicobacter pylori Infection on Allergic Asthma
21
PubMed Central. Helicobacter pylori-Mediated Protection from Allergy Is Associated with IL-10-Secreting Peripheral Blood Regulatory T Cells
22
PubMed Central. Update on the association between Helicobacter pylori infection and asthma in terms of microbiota and immunity
23
PubMed Central. Human and Helicobacter pylori coevolution shapes the risk of gastric disease
24
Revista colombiana de Gastroenterología. A Systematic Review of Genetic Coevolution of Homo Sapiens and Helicobacter Pylori: Implications for Development of Gastric Cancer
25
PubMed. Helicobacter pylori: epidemiology and routes of transmission
26
PubMed Central. Evaluation of urea breath test as a diagnostic tool for Helicobacter pylori infection in adult dyspeptic patients
27
PubMed Central. Diagnostic values of Helicobacter pylori diagnostic tests: stool antigen test, urea breath test, rapid urease test, serology and histology
28
PubMed Central. Treatment of Refractory Helicobacter pylori Infection-Tailored or Empirical Therapy
29
Gut and Liver. Bismuth-Based Quadruple Therapy as First-Line Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Prospective Randomized Comparison of 7- and 14-Day Treatment Regimens
30
PubMed Central. High-Salt Diet Exacerbates H. pylori Infection and Increases Gastric Cancer Risks